Negara: Amerika Serikat
Bahasa: Inggris
Sumber: NLM (National Library of Medicine)
LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL - UNII:E7199S1YWR)
RedPharm Drug Inc.
LISINOPRIL
LISINOPRIL 20 mg
ORAL
PRESCRIPTION DRUG
Lisinopril tablets, USP is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. Lisinopril tablets, USP is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Lisinopril tablets, USP is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. In using lisinopril tablets, USP, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril tablets, USP does not have a similar risk. (See WARNINGS .) In considering the use
Lisinopril Tablets, USP 20 mg, light rust colored, round, flat faced, beveled edge tablets, debossed with “RX 534 ” on one side and plain on the other side. They are supplied as follows: NDC 67296-0542-1 Bottles of 30 Storage Store at 20 – 25° C (68 - 77° F) [See USP Controlled Room Temperature]. Protect from moisture, freezing and excessive heat. Dispense in a tight container. 1 AN69® is a registered trademark of Hospal Ltd. You may report side effects to FDA at 1-800-FDA-1088. Manufactured for: Ranbaxy Pharmaceuticals Inc. Jacksonville, FL 32257 USA by: Ohm Laboratories Inc. North Brunswick, NJ 08902 USA August 2009
Abbreviated New Drug Application
LISINOPRIL - LISINOPRIL TABLET REDPHARM DRUG INC. ---------- LINSOPRIL TABLETS RX ONLY USE IN PREGNANCY WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, ACE INHIBITORS CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS. When pregnancy is detected, lisinopril should be discontinued as soon as possible. See WARNINGS, FETAL/NEONATAL MORBIDITY AND MORTALITY. DESCRIPTION Lisinopril, USP is an oral long-acting angiotensin converting enzyme inhibitor. Lisinopril, USP, a synthetic peptide derivative, is chemically described as (S)-1-[N -(1-carboxy-3-phenylpropyl)-L- lysyl]-L-proline dihydrate. Its molecular formula is C H N O ·2H O and its structural formula is: Lisinopril, USP is a white crystalline powder, with a molecular weight of 441.52. It is soluble in water; sparingly soluble in methanol; practically insoluble in alcohol, in acetone, in acetonitrile and in chloroform. Lisinopril, USP is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration. Inactive Ingredients: 2.5, 5, 10, 20 and 30 mg tablets–dibasic calcium phosphate (anhydrous), ferric oxide (red), magnesium stearate, mannitol, pregelatinized starch, and corn starch. 40 mg tablets-dibasic calcium phosphate (anhydrous), ferric oxide (yellow), magnesium stearate, mannitol, pregelatinized starch, and corn starch. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the rennin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassi Baca dokumen lengkapnya